Brian L Erstad

Brian L Erstad

Department Head, Pharmacy Practice-Science
Professor, Pharmaceutical Sciences
Member of the Graduate Faculty
Professor, BIO5 Institute
Primary Department
Contact
(520) 626-4289

Work Summary

Brian Erstad’s research interests pertain to critical care medicine with an emphasis on patient safety and related outcomes research.

Research Interest

Brian L. Erstad, PharmD, FCCM, is currently a tenured professor and head of the Department of Pharmacy Practice and Science. He is also a center investigator for the Center for Health Outcomes and PharmacoEconomics Research and a co-director for the Arizona Clinical and Translational Research Graduate Certificate Program. His clinical responsibilities are performed at Banner-University Medical Center Tucson.Dr. Erstad’s research interests pertain to critical care medicine with an emphasis on patient safety and related outcomes research. He has authored more than 150 peer-reviewed articles and book chapters.Dr. Erstad has served on the board of directors of the American Society of Health-System Pharmacists and on numerous committees and task forces for other organizations including AHRQ, USP, Society of Critical Care Medicine and the American College of Chest Physicians. He is currently an ad hoc member of the FDA’s Drug Safety and Risk Management Advisory Committee, a steering committee member of the United States Critical Illness and Injury Trials (USCIIT) Group, and treasurer of the American College of Clinical Pharmacy.

Publications

Erstad, B. L., Costa, C. M., Daller, J. A., & Fortune, J. B. (1999). Lack of hematologic effects of recent ethanol ingestion by trauma patients. American Journal of Therapeutics, 6(6), 299-302.

PMID: 11329113;Abstract:

A retrospective investigation was conducted to determine if acute ethanol (EtOH) ingestion before injury leads to hematologic impairment as noted by coagulation and transfusion parameters. Patients older than 18 years of age were grouped according to the presence or absence of detectable EtOH concentrations in the blood, with further subdivision based on an Injury Severity Score of 8 or less or 9 or more. The following direct and indirect indicators of hematologic function were studied: volume of resuscitation fluids administered (including blood products), prothrombin time, partial thromboplastin time, and hematocrit. Of the 304 patients who were evaluated, 152 had detectable EtOH concentrations and 136 had undetectable EtOH concentrations; 16 patients had not been tested for blood EtOH concentrations and were excluded from the analysis. There were no significant differences between groups with regard to blood or fluid requirements or coagulation parameters. Detectable blood EtOH concentrations in trauma patients are not associated with significant changes in transfusion requirements or coagulation parameters compared to patients without detectable EtOH concentrations.

Erstad, B. L., Jordan, C. J., & Thomas, M. C. (2002). Key articles and guidelines relative to intensive care unit pharmacology. Pharmacotherapy, 22(12 I), 1594-1610.

PMID: 12495169;Abstract:

Compilations of key articles and guidelines in a particular clinical practice area are useful not only to clinicians who practice in that area, but to all clinicians. We compiled pertinent articles and guidelines pertaining to drug therapy in the intensive care unit setting from the perspective of an actively practicing critical care pharmacist. This document also may serve to stimulate other experienced clinicians to undertake a similar endeavor in their practice areas.

Erstad, B. L., & Schultz, J. M. (2006). Prophylactic antibiotic compliance with published guidelines. Journal of Pharmacy Practice, 19(5), 301-305.

Abstract:

Purpose: To examine the rate of compliance with National Surgical Infection Prevention Project performance measures and compliance with American Society of Health-System Pharmacists guidelines for procedures not covered by these measures and to evaluate noncompliance for explanatory factors. Methods: A retrospective review of all patients receiving prophylactic antibiotics for Class I (clean) or Class II (clean-contaminated) surgical procedures. Information collected included antibiotic ordered, antibiotic given, dose of antibiotic, time of administration, time of incision, time of closure, duration of procedure, need for re-dosing during the procedure, documentation of re-dosing administered, and antibiotic discontinuation. Results: Choice of antibiotic for prophylaxis was appropriate in 99% of the 568 procedures. Antibiotic was administered too early in 94 of 527 (17.8%) patients. Prophylactic antibiotics were inappropriately continued for more than 24 hours in 43 of 216 (20%) patients undergoing noncardiothoracic procedures and for more than 48 hours in 4 of 10 (40%) in patients undergoing cardiothoracic surgery. Conclusion: Although improvements in key performance measures related to prophylactic antibiotic agent selection, timing of administration, and discontinuation have been made compared to data collected in a larger multicenter study conducted at the beginning of this century, there remains considerable room for improvement. © 2006 Sage Publications.

Erstad, B. L. (1996). Management consultation. American Journal of Health-System Pharmacy, 53(22), 2696+2699.
Erstad, B. L. (2011). Colloids and renal dysfunction: Another brick in the wall of safety concerns. Critical Care Medicine, 39(6), 1565-1566.